Download PDF
Aktuelle Neurologie 2008; 35(4): 177-184
DOI: 10.1055/s-2007-986396
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Immunneuropathien - Von der Pathogenese zur Therapie

Immune-Mediated Neuropathies - From Pathogenesis to TherapyB.  C.  Kieseier1 , H.  C.  Lehmann1 , H.-P.  Hartung1
  • 1Neurologische Klinik, Heinrich-Heine-Universität, Düsseldorf
Further Information

Publication History

Publication Date:
05 May 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Immunneuropathien stellen eine äußerst heterogene Gruppe von zum Teil akut, zum überwiegenden Teil chronisch verlaufenden Erkrankungen mit gravierender Morbidität dar, die das periphere Nervensystem in verschiedenen Facetten betreffen. In den zurückliegenden Jahren konnten große Fortschritte im Verständnis pathogenetisch relevanter Mechanismen erzielt werden. So ist die Rolle von T-Lymphozyten oder die Relevanz von anti-Gangliosid-Antikörpern bei der Schädigung zellulärer Strukturen im peripheren Nerv besser verstanden. Neuere klinische Studien unterstreichen die Bedeutung immunmodulierender und -supprimierender Therapiestrategien, wobei weiterhin Bedarf zur Entwicklung wirksamerer Therapieoptionen besteht, um diese mit Langzeitbehinderung assoziierten Erkrankungen besser behandeln zu können.

Abstract

Immune-mediated neuropathies represent a heterogeneous group of in part acute and, in the majority, chronic diseases affecting the peripheral nerves and still being associated with serious morbidity. In recent years advances in the understanding of pathogenetically relevant mechanisms could be obtained. An emerging body of evidence underlines the role of T lymphocytes or the relevance of anti-ganglioside antibodies in mediating damage to cellular structures within the peripheral nerves. Recent clinical trials point to the impact of immunomodulating and -suppressive drugs in CIDP, however, there is an urgent need for even more powerful treatment strategies in order to prevent long-term disability in patients diagnosed with immune-mediated neuropathies.

Schlüsselwörter

Immunneuropathien - Guillain-Barré-Syndrom - CIDP - Therapie

Key words

immune neuropathies - Guillain-Barré syndrome - CIDP - therapy

Literatur

  • 1 Hughes R AC, Cornblath D R. Guillain-Barré syndrome.  Lancet. 2005;  366 1653-1666
    CrossrefPubMedGoogle Scholar
  • 2 Köller H, Kieseier B C, Jander S. et al . Chronic inflammatory demyelinating polyneuropathy.  N Engl J Med. 2005;  352 1343-1356
    CrossrefPubMedGoogle Scholar
  • 3 Hughes R AC. The concept and classification of Guillain-Barré syndrome and related disorders.  Rev Neurol (Paris). 1995;  151 291-294
    PubMedGoogle Scholar
  • 4 Feasby T E. Axonal Guillain-Barré syndrome.  Muscle Nerve. 1994;  17 678-679 , (Brain 1996; 119: 1055 - 1066)
    CrossrefPubMedGoogle Scholar
  • 5 Willison H J, O'Hanlon G M. The immunopathogenesis of Miller Fisher syndrome.  J Neuroimmunol. 1999;  100 3-12
    CrossrefPubMedGoogle Scholar
  • 6 Hughes R AC, Wijdicks E F, Barohn R. et al . Practice parameter: Immunotherapy for Guillain-Barré syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2003;  61 736-740
    CrossrefPubMedGoogle Scholar
  • 7 Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia.  Muscle Nerve. 1999;  22 1071-1074
    CrossrefPubMedGoogle Scholar
  • 8 Koga M, Yuki N, Ariga T. et al . Is IgG anti-GT1a antibody associated with pharyngeal-cervical-brachial weakness or oropharyngeal palsy in Guillain-Barré syndrome?.  J Neuroimmunol. 1998;  86 74-79
    CrossrefPubMedGoogle Scholar
  • 9 Ropper A H. Unusual clinical variants and signs in Guillain-Barré syndrome.  Arch Neurol. 1986;  43 1150-1152
    CrossrefPubMedGoogle Scholar
  • 10 O'Leary C P, Veitch J, Durward W F. et al . Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides.  J Neurol Neurosurg Psychiatry. 1996;  61 649-651
    PubMedGoogle Scholar
  • 11 Katz J S, Saperstein D S, Gronseth G. et al . Distal acquired demyelinating symmetric neuropathy.  Neurology. 2000;  54 615-620
    CrossrefPubMedGoogle Scholar
  • 12 Saperstein D S, Katz J S, Amato A A, Barohn R J. Clinical spectrum of chronic acquired demyelinating polyneuropathies.  Muscle Nerve. 2001;  24 311-324
    CrossrefPubMedGoogle Scholar
  • 13 Van den Berg-Vos R M, van den Berg L H, Franssen H. et al . Multifokal inflammatory demyelinating polyneuropathy. A distinct clinical entitiy?.  Neurology. 2000;  54 26-32
    CrossrefPubMedGoogle Scholar
  • 14 Hughes R AC, Umapathi T, Gray I A. et al . A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy.  Brain. 2004;  127 1723-1730
    CrossrefPubMedGoogle Scholar
  • 15 Sabatelli M, Madia F, Mignogna T. et al . Pure motor chronic inflammatory demyelinating polyneuropathy.  J Neurol. 2001;  248 772-777
    PubMedGoogle Scholar
  • 16 Dyck P J, Dyck P JB. Atypical varieties of chronic inflammatory demyelinating neuropathies.  Lancet. 2000;  355 1293-1294
    CrossrefPubMedGoogle Scholar
  • 17 Hughes R AC, Bensa S, Willison H. et al . Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.  Ann Neurol. 2001;  50 195-201
    CrossrefPubMedGoogle Scholar
  • 18 The French CIDP Study Group . Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy.  J Neurol Neurosurg Psychiatry. 2008;  79 115-118
    CrossrefPubMedGoogle Scholar
  • 19 Meyer zu Hörste G, Hartung H P, Kieseier B C. From bench to bedside - experimental rationale for immune-specific therapies in the inflamed peripheral nerve.  Nat Clin Pract Neurol. 2007;  3 198-211
    PubMedGoogle Scholar
  • 20 Hu W, Dehmel T, Pirhonen J. et al . Interleukin-23 in acute inflammatory demyelination of the peripheral nervous system.  Arch Neurol. 2006;  63 858-864
    CrossrefPubMedGoogle Scholar
  • 21 Hu W, Janke A, Ortler S. et al . Expression of CD28 related costimulatory molecule and its ligand in inflammatory neuropathies.  Neurology. 2007;  68 277-282
    CrossrefPubMedGoogle Scholar
  • 22 Willison H J, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies.  Brain. 2002;  125 2591-2625
    CrossrefPubMedGoogle Scholar
  • 23 Yuki N. Carbohydrate mimicry: a new paradigm of autoimmune diseases.  Curr Opin Immunol. 2005;  17 577-582
    CrossrefPubMedGoogle Scholar
  • 24 Griffin J W, Li C Y, Ho T W. et al . Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases.  Brain. 1995;  118 577-595
    PubMedGoogle Scholar
  • 25 Lehmann H C, Koehne A, Meyer zu Hörste G. et al . Role of nitric oxide as mediators of nerve injury in inflammatory neuropathies.  J Neuropathol Exp Neurol. 2007;  66 305-312
    CrossrefPubMedGoogle Scholar
  • 26 Khalili-Shirazi A, Atkinson P, Gregson N, Hughes R A. Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy.  J Neuroimmunol. 1993;  46 245-251
    CrossrefPubMedGoogle Scholar
  • 27 Quattrini A, Previtali S C, Kieseier B C. et al . Autoimmunity in the peripheral nervous system.  Critical Reviews in Neurobiology. 2003;  15 1-39
    CrossrefPubMedGoogle Scholar
  • 28 Steck A J, Stalder A K, Renaud S. Anti-myelin-associated glycoprotein neuropathy.  Curr Opin Neurol. 2006;  19 458-463
    PubMedGoogle Scholar
  • 29 Lehmann H C, Hartung H P, Hetzel G R. et al . Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders.  Arch Neurol. 2006;  63 1066-1071
    CrossrefPubMedGoogle Scholar
  • 30 The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome . Appropriate number of plasma exchanges in Guillain-Barré syndrome.  Ann Neurol. 1997;  41 298-306
    CrossrefPubMedGoogle Scholar
  • 31 Gold R, Stangel M, Dalakas M C. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues.  Nat Clin Pract Neurol. 2007;  3 36-44
    PubMedGoogle Scholar
  • 32 Pritchard J, Gray I A, Idrissova Z R. et al . A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.  Neurology. 2003;  61 1282-1284
    CrossrefPubMedGoogle Scholar
  • 33 Jacobs B C, van Doorn P A, Schmitz P I. et al . Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome.  Ann Neurol. 1996;  40 181-187
    CrossrefPubMedGoogle Scholar
  • 34 Rotta F T, Sussman A T, Bradley W G. et al . The spectrum of chronic inflammatory demyelinating polyneuropathy.  J Neurol Sci. 2000;  173 129-139
    CrossrefPubMedGoogle Scholar
  • 35 Yuki N, Ang C W, Koga M. et al . Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside.  Ann Neurol. 2000;  47 314-321
    CrossrefPubMedGoogle Scholar
  • 36 Kieseier B C, Kiefer R, Gold R. et al . Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.  Muscle Nerve. 2004;  30 131-156
    CrossrefPubMedGoogle Scholar
  • 37 Hughes R AC, Swan A V, Raphael J C. et al . Immunotherapy for Guillain-Barré syndrome: a systematic review.  Brain. 2007;  130 2245-2257
    CrossrefPubMedGoogle Scholar
  • 38 Guillain-Barré Syndrome Steroid Trial Group . Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome.  Lancet. 1993;  341 586-590
    PubMedGoogle Scholar
  • 39 van Koningsveld R, Schmitz P I, Meché F G. et al . Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.  Lancet. 2004;  363 192-196
    CrossrefPubMedGoogle Scholar
  • 40 Köller H, Schroeter M, Kieseier B C, HP H artung. Chronic inflammatory demyelinating neuropathy - update on pathogenesis, diagnostic criteria and therapy.  Curr Opin Neurol. 2005;  18 273-278
    PubMedGoogle Scholar
  • 41 Kieseier B C, Wiendl H, Hartung H P. The inflamed peripheral nervous system: update on immune therapies.  Curr Opin Neurol. 2006;  19 433-436
    CrossrefPubMedGoogle Scholar
  • 42 Gold R, Kieseier B C. Therapy of immune neuropathies with intravenous immunoglobulins.  Journal of Neurology. 2006;  253 59-63
    CrossrefPubMedGoogle Scholar
  • 43 Hughes R AC, Donofrio P, Bril V. et al . Intravenous immune globulin (10 % caprylatechromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.  Lancet Neurol. 2008;  7 136-144
    CrossrefPubMedGoogle Scholar
  • 44 Köller H, Schroeter M, Feischen H. et al . Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies.  J Neurol. 2006;  253 1505-1506
    PubMedGoogle Scholar
  • 45 Lee D H, Linker R A, Paulus W. et al .Subcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008; in press
    Google Scholar
  • 46 Kieseier B C, Dalakas M C, Hartung H P. Immune mechanisms in chronic inflammatory demyelinating neuropathy.  Neurology. 2002;  59 7-12
    PubMedGoogle Scholar
  • 47 Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies.  Muscle Nerve. 2005;  31 663-680
    CrossrefPubMedGoogle Scholar
  • 48 Federico P, Zochodne D W, Hahn A F. et al . Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled study.  Neurology. 2000;  55 1256-1262
    CrossrefPubMedGoogle Scholar
  • 49 Koski C L. Initial and long-term management of autoimmune neuropathies.  CNS Drugs. 2005;  19 1033-1048
    CrossrefPubMedGoogle Scholar
  • 50 Umapathi T, Hughes R A, Nobile-Orazio E, Leger J M. Immunosuppressive treatment for multifocal motor neuropathy.  Cochrane Database Syst Rev. 2002;  , CD003217
    PubMedGoogle Scholar
  • 51 Lehmann H C, Hoffmann F, Meyer zu Hörste G. et al .The clinical value of therapeutic plasma exchange in multifocal motor neuropathy. J Neurol Sci 2008; in press
    Google Scholar
  • 52 Dyck P J, Daube J, O'Brien P. et al . Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy.  N Engl J Med. 1986;  314 461-465
    CrossrefPubMedGoogle Scholar
  • 53 Hahn A F, Bolton C F, Pillay N. et al . Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.  Brain. 1996;  119 1055-1066
    CrossrefPubMedGoogle Scholar
  • 54 Lehmann H C, Hartung H P, Hetzel G R, Kieseier B C. Plasmapherese als Therapieoption bei neurologischen Erkrankungen.  Der Nervenarzt. 2007;  78 166, 168 - 170, 172 - 176
    PubMedGoogle Scholar
  • 55 Mehndiratta M M, Hughes R A. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.  Cochrane Database Syst Rev. 2002;  , CD002062
    PubMedGoogle Scholar
  • 56 Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.  Arch Neurol. 2005;  62 249-254
    CrossrefPubMedGoogle Scholar
  • 57 Dyck P J, O'Brien P, Swanson C. et al . Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy.  Neurology. 1985;  35 1173-1176
    CrossrefPubMedGoogle Scholar
  • 58 Fialho D, Chan Y C, Allen D C. et al . Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate.  J Neurol Neurosurg Psychiatry. 2006;  77 544-547
    CrossrefPubMedGoogle Scholar
  • 59 Mahattanakul W, Crawford T O, Griffin J W. et al . Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A.  J Neurol Neurosurg Psychiatry. 1996;  60 185-187
    CrossrefPubMedGoogle Scholar
  • 60 Visudtibhan A, Chiemchanya S, Visudhiphan P. Cyclosporine in chronic inflammatory demyelinating polyradiculoneuropathy.  Pediatr Neurol. 2005;  33 368-372
    CrossrefPubMedGoogle Scholar
  • 61 Frohman E M, Brannon K, Racke M K, Hawker K. Mycophenolate mofetil in multiple sclerosis.  Clin Neuropharmacol. 2004;  27 80-83
    PubMedGoogle Scholar
  • 62 Schneider-Gold C, Hartung H P, Gold R. Mycophenolate mofetil and tacrolimus: New therapeutic options in neuroimmunological diseases.  Muscle Nerve. 2006;  34 284-291
    CrossrefPubMedGoogle Scholar
  • 63 Gorson K C, Amato A A, Ropper A H. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy.  Neurology. 2004;  63 715-717
    CrossrefPubMedGoogle Scholar
  • 64 Piepers S, van den Berg-Vos R, van der Pol W L. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.  Brain. 2007;  130 2004-2010
    CrossrefPubMedGoogle Scholar
  • 65 Gladstone D E, Prestrud A A, Brannagan T H. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy.  J Peripher Nerv Syst. 2005;  10 11-16
    CrossrefPubMedGoogle Scholar
  • 66 Glennie M J, French R R, Cragg M S, Taylor R P. Mechanisms of killing by anti-CD20 monoclonal antibodies.  Mol Immunol. 2007;  44 3823-3837
    CrossrefPubMedGoogle Scholar
  • 67 Renaud S, Gregor M, Fuhr P. et al . Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.  Muscle Nerve. 2003;  27 611-615
    PubMedGoogle Scholar
  • 68 Renaud S, Fuhr P, Gregor M. et al . High-dose rituximab and anti-MAG-associated polyneuropathy.  Neurology. 2006;  66 742-744
    CrossrefPubMedGoogle Scholar
  • 69 Ruegg S J, Fuhr P, Steck A J. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.  Neurology. 2004;  63 2178-2179
    PubMedGoogle Scholar
  • 70 Broglio L, Lauria G. Worsening after rituximab treatment in anti-mag neuropathy.  Muscle Nerve. 2005;  32 378-379
    CrossrefPubMedGoogle Scholar
  • 71 Browning J L. B cells move to centre stage: novel opportunities for autoimmune disease treatment.  Nat Rev Drug Discov. 2006;  5 564-576
    CrossrefPubMedGoogle Scholar
  • 72 Hirst C, Raasch S, Llewelyn G, Robertson N. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).  J Neurol Neurosurg Psychiatry. 2006;  77 800-802
    PubMedGoogle Scholar
  • 73 Report from an ad hoc subcommittee of the American Academy of Neurology AIDS Task Force . Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).  Neurology. 1991;  41 617-618
    PubMedGoogle Scholar

Prof. Dr. Bernd C. Kieseier

Neurologische Klinik, Heinrich-Heine-Universität

Moorenstr. 5

40225 Düsseldorf

Email: bernd.kieseier@uni-duesseldorf.de